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IGABT was based on MRI in 82% of the patients. Sixty percent were 
treated with high dose rate and the remaining 40% had pulsed dose 
rate BT. Eighty-four percent of the patients were treated with 
intracavitary (IC) technique. In the remaining 16% a combined IC and 
interstitial applicator was used.  
Results: Total prescribed mean dose for HR-CTV (D90) was 89 ±15 Gy, 
D2cc was 89 ±12 Gy for bladder, 64 ±8 Gy for rectum and 65 ±10 Gy for 
sigmoid. At a median follow-up of 31 (3-150) months, two patients had 
died due to morbidity (one fistula and one vaginal bleeding). No other 
G5 events were diagnosed. Actuarial morbidity G3-G5 at 5-years was 
4% for UG tract, 6% for GI tract and 4% for VG. Actuarial morbidity G2-
G5 at 5-years was 19% for UG tract, 18% for GI tract and 22% for VG.  
Conclusions: In this retrospective multicentre study 3D conformal RT 
± cisplatinum and IGABT compares favourble with previous studies on 
morbidity after 2D BT. These findings illustrate that the GEC-ESTRO 
guidelines work in a multicentre setting and serve as benchmark for 
future studies on IGABT for cervical cancer. 
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Purpose/Objective: To give a first interim report on prospectively 
assessed vaginal morbidity in the ongoing EMBRACE study (European 
and International study on MRI-guided brachytherapy in locally ad-
vanced cervical cancer, www.embracestudy.dk) and to describe a 
dose response relationship. Currently, no dose response relationship 
for vaginal morbidity has been established.  
Materials and Methods: Patients with locally advanced cervical 
cancer who underwent combined external beam radiotherapy ± 
chemotherapy and MRI-guided brachytherapy following the GEC-ESTRO 
guidelines were included. Vaginal morbidity was prospectively as-
sessed with CTCAE v.3 at baseline and every 3 months after end of 
treatment for the first 2 years. The assessment included vaginal 
dryness, mucositis, bleeding, stenosis, fistula and any other vaginal 
symptoms (reported in free text field). The dose to the ICRU rectal 
point was used as a surrogate for intermediate to high dose to the 
upper vagina in order to establish a dose effect relationship for vagin-
al morbidity with binary logistic regression analysis (dose response 
curves). 
Results: Information on vaginal morbidity was available in 523 pa-
tients from 19 centers for analysis. Median follow-up was 14 months 
(286 patients with one year and 108 patients with 2 year follow-up). 
Crude incidences of individual vaginal symptoms are shown in table 1; 
no G5 morbidity occurred.  
 Most frequent other vaginal symptoms were adhesions. Actuarial 
analyses resulted in 78% probability of any vaginal morbidity G≥1 and 
19% G≥2 after 1 year, and 92% and 34% after 2 years. In 468 patients, 
information on vaginal morbidity and dose to the ICRU rectal point 
was available. In univariate logistic regression analysis, dose to the 
ICRU rectal point was associated with higher frequency of G≥2 vaginal   
morbidity (p= 0.002, figure 1).   
    
  
 
Conclusions: Severe vaginal morbidity (G3/G4) is rare in the first two 
years after definitive radiochemotherapy including MRI-guided adap-
tive brachytherapy. However, the probability for milder to moderate 
morbidity (G1/G2) is high in the first year (78%) and further increases 
in the second year (92%). The ICRU rectal point dose correlates signif-
icantly with occurrence of G2≥2 vaginal morbidity. Further investiga-
tions with longer follow-up, including the relevance of confounding 
factors, are required. Additionally, analyses of individual vaginal 
endpoints and further dose parameters at the lower and middle 
vagina, especially also sensitive to external beam, are planned and 
will allow in future more detailed conclusions.  
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Purpose/Objective: The purpose of this study was to determine 
feasibility of salvage re-irradiation with high dose rate (HDR) 
brachytherapy and patterns of failures in previously irradiated 
patients diagnosed with recurrent carcinoma of the uterine cervix. 
Materials and Methods: Twenty-eight previously irradiated patients 
presenting with central recurrence with / without early parametrial 
disease and deemed not suitable for exenteration surgery by Gynec 
oncologist, were treated with salvage re-irradiation using HDR 
brachytherapy at our institute. All these patients underwent imaging 
(CT / MR/ PET-CT) to rule out metastatic disease elsewhere in the 
body. Martinez Universal Perineal Interstitial Template (MUPIT) was 
used in 24 patients while Vienna applicator in 4 patients. Median age 
for the cohort was 54 years (range 38-73 years). Median interval 
between two radiation schedules was 25 months (inter-quartile range 
13-49 months). Median delivered dose was 40.3 Gy EQD2 (inter-
quartile range 36.9 - 46.6 Gy). None of the patients received any form 
of Chemotherapy (concomitant / adjuvant /salvage). 
Results: All patients tolerated salvage re-irradiation with HDR 
brachytherapy well. None of the patients reported any significant 
acute toxicity. The median follow up for whole group was 16 months 
(inter-quartile range 7-20 months). Complete response was seen in 21 
patients, partial response in 6 patients and progressive disease in one 
patient on clinic-radiological assessment. At last follow up 15 patients 
were alive, of which 13 were diseases free. Ten patients developed 
central recurrence (biopsy proven), 3 patients had loco-regional 
recurrence while 2 patients had distant metastases. Overall, 
13/28patients developed local recurrence. The local recurrence rate 
was higher inpatients receiving doses less than 40 Gy EQD2.The 
median disease free survival(DFS) and overall survival (OS) was 16 and 
20 months respectively. Two year DFS and OS were 33% and 44% 
respectively. Median DFS was more for patients with more than 25 
month interval between two RT schedules, while tumour size and RT 
dose had no impact on overall DFS. Two patients developed grade III 
radiation proctitis, 3 patients had grade II radiation cystitis and 2 
patients developed grade II bowel complications after re-irradiation. 
One patient required hyperbaric oxygen therapy for chronic non-
healing ulcer at vagina.  
Conclusions: Salvage re-irradiation using HDR brachytherapy is 
feasible in select group of patients with central recurrence. The 
